Eli Lilly and Company (NYSE:LLY) says its newly launched oral obesity drug Foundayo has captured more than 30% of new U.S. patients starting oral weight-loss medicines, a notable early gain against Novo Nordisk's Wegovy pill. Reuters reports that Wegovy initially held roughly 90% of the oral market, making Lilly's rapid share capture an important sign that the oral GLP-1 market is becoming a two-player competition rather than a Novo-dominated segment. The broader U.S. obesity-drug market is expected to exceed $100 billion annually by 2030, with oral treatments potentially accounting for more than one-third of GLP-1 use. The timing is strategically important for Lilly because Foundayo was only launched in the U.S. in April 2026.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.